智通财经APP获悉，周一，礼来(LLY.US)涨逾2%，报752.61美元。消息面上，当地时间5月11日，礼公布的对比试验数据显示，其减肥药物Zepbound的减重效果，要比竞争对手诺和诺德的同类药物Wegovy高近50%。
在《新英格兰医学杂志》上发布的对照研究结论表明，使用Zepbound的患者在经过72周的治疗后体重平均减轻了50磅(约22.8公斤)，而使用Wegovy的患者体重减轻了约33磅(约15公斤)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.